Retrophin to Present at September Investor Conferences

SAN DIEGO, Sept. 11, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at two upcoming investor conferences in New York City, including:

Cantor Fitzgerald Global Healthcare Conference
Date: Monday, September 25, 2017
Time: 9:45 a.m. ET

Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Date: Wednesday, September 27, 2017
Time: 1:30 p.m. ET

Live webcasts will be available at http://ir.retrophin.com/events, and archived replays will be accessible for up to 30 days.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola^®, Cholbam^® and Chenodal^®. retrophin.com

Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]